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Abstract
Background: Infection with hepatitis B virus (HBV) in pregnant women may be a threat for both mothers and
fetuses. This study was performed to explore the impact of maternal HBV carrier status on pregnancy outcomes.
Methods: We conducted a prospective cohort study at the Obstetrics & Gynecology Hospital of Nantong University
between January 1, 2012 and September 30, 2015. A consecutive sample of 21,004 pregnant women, 513
asymptomatic HBV carriers and 20,491 non-HBV controls, was included in this study. The main outcomes of interest
were selected pregnancy outcomes including miscarriage, stillbirth, preterm birth (PTB), gestational diabetes (GDM),
intrahepatic cholestasis of pregnancy (ICP), preterm premature rupture of the membrane (PPROM), low birth weight
(LBW), small for gestational age (SGA) and Apgar scores. The incidence of adverse pregnancy outcomes between
asymptomatic HBV carriers and non-HBV controls were compared using the chi-square test and logistic regression.
P values were two sided, and P <0.05 was considered to indicate statistical significance.
Results: The incidences of stillbirth, PTB, GDM, ICP, PPROM, LBW, and SGA were similar between the HBV carrier
and non-HBV groups. The proportion of miscarriage was significantly higher among the HBV carriers than the
controls (9.36 % vs 5.70 %; P <0.001). After using multivariate modelling to adjust for possible socio-demographical
variables and obstetric complications, women with HBV carrier status were still more likely to have miscarriage
(adjusted OR 1.71, 95 % CI 1.23–2.38). In addition, the incidences of other maternal and neonatal outcomes were
similar between the two groups.
Conclusion: Maternal HBV carrier status may be an independent risk factor for miscarriage and careful surveillance
is warranted.
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Background
Hepatitis B virus (HBV) infection is one of the most
common health problems worldwide. The prevalence of
HBV infection among women of childbearing age may
be as high as 2–8 % in China [1, 2], whereas in the USA
it is only 0.4 % [3]. Most pregnant women with HBV
infection are chronic carriers, indicated by positive
serum hepatitis B surface antigen (HBsAg) status.
HBsAg expression has also been found in cells of the
ovarian follicle or placental capillary endothelium [4].
Intrauterine infection and vertical transmission of HBV
is a fundamental reason why there are so many chronic
HBV carriers in China. The overall estimated rates of
immunoprophylaxis failure for infants with HBsAg-
positive and HBeAg-positive mothers were 4.87 and
9.66 % respectively [5].
Although HBV carrier status is relatively common
among pregnant women, especially in highly endemic
countries such as China, there is a paucity of data
regarding the impact of maternal HBV infection on the
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risk for adverse pregnancy outcomes. The limited studies
on this issue have always yielded conflicting results [6–15].
Due to this dearth of information, we undertook this
hospital-based prospective cohort study, which seeks to
examine the association of HBV carrier status with
pregnancy outcomes.
Methods
Study design and participant population
We conducted a prospective cohort study at the Obstet-
rics & Gynecology Hospital of Nantong University,
China between January 1, 2012 and September 30, 2015.
All pregnant women who visited the tertiary teaching
hospital were screened and recruited through 2012 to
2014. Data on maternal characteristics (age, education,
medical history) were taken from questionnaires com-
pleted by women after their first antenatal visit. Body
mass index (BMI) was classified according to the WHO
classification: underweight (<18.5 kg/m2), normal weight
(18.5–24.9 kg/m2), overweight (25–29.9 kg/m2) or obes-
ity (≥30 kg/m2) [16]. As part of standard prenatal care at
our hospital, all women are screened in the first trimes-
ter of pregnancy for hepatitis B surface antigen (HBsAg),
hepatitis B e antigen (HBeAg), IgG antibodies against
HCV and HIV, syphilis tests with the treponema palli-
dum particle agglutination assay (TP-PA) and RPR,
specific IgM antibodies against toxoplasma, rubella virus,
CMV and HSV-1/2.
All enrolled participants fulfilled the following criteria:
(i) normal alanine transaminase (ALT) at study entry; (ii)
no evidence of hepatitis C virus (HCV) infection (anti-
HCV negative), (iii) absence of human immunodefi-
ciency virus (HIV) infection (anti-HIV negative) and ac-
tive syphilis infection (rapid plasma reagin test/RPR
negative); (iv) absence of IgM antibodies against toxo-
plasma (TOX), rubella virus (RV), cytomegalovirus
(CMV), herpes simplex virus (HSV-1/2); (v) exclusion of
other liver diseases such as alcoholic liver diseases
(ALDs), nonalcoholic fatty liver diseases (NAFLDs) or
autoimmune liver diseases (AILDs); (vi) absence of pre-
existing chronic diseases such as diabetes mellitus,
hypertension, or heart diseases. HBV carriers were de-
fined as: HBsAg positivity >6 months confirmed by
previous medical history, and persistently normal levels
of ALT before and at study entry. In addition, HBV
carriers were excluded if they had received antiviral
treatment within the previous year.
A total of 24,713 pregnant women were reviewed and
screened in their first trimester of pregnancy at the Ob-
stetrics & Gynecology Hospital of Nantong University,
China. Of these, 3382 were excluded: due to abnormal
ALT or other liver diseases (HCV infection, ALDs,
NAFLDs, or AILDs) in 1065 subjects; due to other infec-
tion (HIV infection, active syphilis infection, positivity of
anti-TOX IgM, anti-RV IgM, anti-CMV IgM or anti-
HSV IgM) in 1788 subjects; due to concurrent medical
complications (DM, hypertension or heart diseases) in
529 subjects. Thereafter, 21,331 pregnant women were
enrolled in this study, including 519 asymptomatic HBV
carriers and 20,812 non-HBV controls. Most of the
enrolled subjects received at least three health examina-
tions and were followed-up until delivery or miscarriage.
327 subjects were excluded because of the following
reasons: acute hepatitis in 35 subjects (hepatitis E in 27
subjects and hepatitis A in eight subjects); lost to follow-
up in 159 subjects; incomplete data in 133 subjects.
Finally, 21,004 subjects, with 513 asymptomatic HBV
carriers (HBeAg positive in 159 subjects) and 20,491
non-HBV controls, were included to evaluate the
effect of chronic HBV carrier status on the pregnancy
outcomes (Fig. 1).
The study protocol was approved by the institutional
ethics committee of the Obstetrics & Gynecology
Hospital of Nantong University and conducted in accord
with the guidelines of the Declaration of Helsinki. Written
informed consent was obtained from each patient.
Pregnancy outcomes
Primary pregnancy outcomes were: miscarriage (spon-
taneous abortion), preterm (<37w), or stillbirth (after 20
completed gestational weeks). Other maternal outcomes
included preeclampsia, gestational diabetes (GDM),
placenta previa, placental abruption, and preterm pre-
mature rupture of the membranes (PPROM). Neonatal
outcomes for singleton pregnancy included low birth
weight (LBW, <2,500 g) or macrosomia (≥4,000 g),
small for gestational age (SGA; defined as a birth
weight below the 10th percentile for each gestational
age using sex-specific criteria) [17, 18] and Apgar score
(<7 at 5 min). The rate of cesarean section was not
assessed because China has nearly 50 % caesarean
delivery rate due to “social influence” rather than
medical or obstetric indication [19].
Statistical analysis
According to a recent survey conducted in China, the
prevalence of HBsAg among pregnant women was 6.1 %
[1]. With the assumption that the ratio of HBV carriers
to non-HBV subjects was 1:20, the baseline risk for
adverse pregnancy outcome was 5 % and there might be
2-fold increase of risk with a power of 80 %, the mini-
mum sample size of approximately 4200 participants
including 200 HBV carriers were required.
The continuous data were expressed as mean ± standard
deviation (SD) and categorical data as number or percent.
Comparison of continuous variables was done by student
t test. For categorical variables the chi-square or Fisher’s
exact test were used. Selected maternal and neonatal
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outcomes in all pregnancies or singleton pregnancies
were calculated per woman and/or per infant when
appropriate. In this analysis, miscarriage was taken as
the dependent variable. Demographic, education, med-
ical history, and laboratory factors were taken as
independent variables. Risk factors found significant
on univariate analysis were entered into multivariate
logistic regression model. All statistical tests were 2-tailed,
and a significance level (P) of 0.05 was used. The




The demographic and clinical data of 21,004 study
subjects are shown in Table 1. The mean age (SD) of the
asymptomatic HBV carrier group was slightly but signifi-
cantly older than that of the control group (27.59 ± 4.02
vs. 27.03 ± 4.19 years, P <0.01). But no significant
difference was found between the two groups in terms
of the proportion of older pregnant women (aged
35 years or more). HBV carriers also had significantly
higher serum ALT levels than controls (24.75 ± 7.22 vs.
22.34 ± 6.49 U/L, P < 0.001). Moreover, there was no sig-
nificant difference in terms of height, pre-maternal BMI,
education level, parity, history of miscarriage or preterm
birth, plurality, and in vitro fertilization (IVF) between
the HBV carriers and the controls.
During the follow-up, 20885 patients had persistently
normal levels of serum ALT, while 119 (0.57 %) patients
experienced at least one episode of ALT > the upper
limit of normal (ULN, 40U/L). Among them, 6 HBV
carriers and 112 non-HBV controls showed a mild ALT
increase (≤2ULN), while only 1 non-HBV subject
showed a moderate ALT increase (>2ULN). All the ALT
elevation was transient and usually recovered to normal
levels within 3 months.
Pregnancy outcomes
The mean (SD) of completed weeks’ gestation was signifi-
cantly shorter in HBV carriers than in the non-HBV
controls (35.79 ± 8.29 vs. 36.95 ± 6.76; P <0.001). The
proportion of miscarriage was significantly higher among
the HBV carriers than the controls (9.36 % vs 5.70 %;
P <0.001). Meanwhile, there was no significant difference
between the two groups for most of the pregnancy
Fig. 1 Flow chart for study population. HBV, hepatitis B virus; ALT, alanine transaminase; HCV, hepatitis C virus; HIV human immunodeficiency
virus; RPR, rapid plasma reagin test; TOX, toxoplasma; RV, rubella virus; CMV, cytomegalovirus, HSV, herpes simplex virus; ALD, alcoholic liver
disease; NAFLD, nonalcoholic fatty liver diseases; AILD, autoimmune liver disease; DM, diabetes mellitus
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outcomes such as preterm birth, stillbirth, GDM, ICP,
placenta previa or PPROM (Table 2).
In singleton pregnancy, the rate of miscarriage was
also significantly higher in HBV carrier group than in
the control group (9.66 % vs. 5.81 %, P <0.001). Preterm
birth occurred in 36/497 (7.24 %) and 1462/20,001
(7.31 %) of pregnancies in HBV carrier and control
group respectively (P >0.05). The mean (SD) birth
weight was 3311.26 (510.34) g and 3330 (509.08) g in
the two groups respectively (P >0.05). Comparable
neonatal adverse outcomes occurred in the two groups
(e.g., <1,500 g: 0.80 % vs. 0.54 %; <2,500 g: 5.03 % vs.
4.52 %; SGA: 4.43 % vs. 5.16 %; respectively). There were
no significant differences in incidences of perinatal
mortality or Apgar score <7 at 5 min (Table 3).
Risk factors associated with miscarriage
Table 4 presents crude and adjusted odds ratios (ORs)
and 95 % confidence intervals (CIs) of miscarriage
associated with demographic, physical, reproductive and
laboratory characteristics. When single factors were
analyzed for the risk of miscarriage, five factors had been
Table 1 Baseline characteristics of the study populationa
Characteristic HBV carriers (n = 513) Controls (n = 20491) P
Maternal age (y) 27.59 ± 4.02 27.03 ± 4.19 0.003
≤19 2 239 0.234
20–34 476 18,974
≥35 (older pregnancy) 35 12,78
Height (cm) 156.23 ± 8.43 155.81 ± 7.32 0.201
Pre-pregnancy BMI 22.34 ± 5.86 22.02 ± 5.69 0.209





Primary/under 15 892 0.288
Middle/High school 171 6,785
College/above 327 12,814
Parity




0 456 18,607 0.385
1 42 1,329
≥2 15 555





1 497 20,001 0.288
≥2 16 490
IVF
No 509 20,344 0.869
Yes 4 147
ALT (U/L) 24.75 ± 7.22 22.34 ± 6.49 <0.001
Abbreviations: BMI body mass index, IVF in vitro fertilization
aValues are reported as mean ± SD, compared with t test, or number, compared with χ2 test, unless otherwise indicated
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identified: (i) history of miscarriage with crude OR of
7.95 (95 % CI 6.85–9.22) for once and crude OR of 18.89
(95 % CI 15.72–22.71) for twice or more respectively; (ii) in
vitro fertilization (crude OR 2.37, 95 % CI 1.46–3.84); (iii)
older age (crude OR 2.22, 95 % CI 1.85–2.66); (iv) HBV
carrier status (crude OR 1.71, 95 % CI 1.26–2.31); and (v)
nulliparity (crude OR 1.48, 95 % CI 1.31–1.69). We did not
find the association of education level, pre-maternal BMI
with miscarriage risk. Furthermore, we examined the covar-
iates associated with miscarriage using multivariable logistic
Table 2 Comparison of the pregnancy outcomes between asymptomatic HBV carriers and non-HBV controlsa
Outcome HBV carriers (n = 513) Controls (n = 20,491) P
Completed weeks’ gestation 35.79 ± 8.29 36.95 ± 6.76 <0.001
≤12 wks 36 822 0.002
12 1/7 to 28 wks 13 390
28 1/7 to 40 wks 369 14,755
>40 wks 95 4,524
Preterm birth 49 (9.55 %) 1,718 (8.38 %) 0.347
Stillbirth 0 18 (0.09 %) 0.502
Miscarriage 48 (9.36 %) 1,167 (5.70 %) <0.001
Preeclampsia 4 (0.78 %) 216 (1.05 %) 0.600
GDM 6 (1.17 %) 232 (1.13 %) 0.937
ICP 12 (2.34 %) 331 (1.62 %) 0.201
Placenta previa 4 (0.78 %) 216 (1.05 %) 0.547
PPROM 23 (4.48 %) 845 (4.12 %) 0.686
Abbreviations: GDM Gestational diabetes, ICP intrahepatic cholestasis of pregnancy, PPROM preterm premature rupture of the membrane
aValues are reported as mean ± SD, compared with t test, or number (percentage), compared with χ2 test, unless otherwise indicated
Table 3 Neonatal outcomes in singleton pregnancya
Outcome HBV carriers (n = 497) Controls (n = 20,001) P
Full-term birth 413 (83.10 %) 17,364 (86.82 %) 0.016
Preterm birth 36 (7.24 %) 1462 (7.31 %) 0.955
Stillbirth 0 12 (0.06 %) 0.585
Miscarriage 48 (9.66 %) 1163 (5.81 %) <0.001
Weight of neonates (g) 3311.26 ± 510.34 3330 ± 509.08 0.436
Unknown 0 9
<1500 g 4 108 0.585
1500–2500 g 21 797
2500–3999 g 392 17,489
≥4000 g 32 1,598
LBW
Unknown 0 9
No 472 19,087 0.594
Yes 25 905
SGA <10 centile
Unknown 0 9 0.461
No 475 18,959
Yes 22 1,033
Apgar at 5 min 9.90 ± 0.53 9.87 ± 0.69 0.336
≥7 488 19,744 0.292
<7 9 257
Abbreviations: LBW low birth weight, SGA small for gestational age
aValues are reported as mean ± SD, compared with t test, or number (percentage), compared with χ2 test, unless otherwise indicated
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regression. Factors independently associated with miscar-
riage were: prior abortion (adjusted OR 9.33 for once, ad-
justed OR 23.36 for twice or more), nulliparity (adjusted
OR 1.80), IVF (adjusted OR 1.78), and HBV carrier status
(adjusted OR 1.71).
Discussion
Our prospective cohort study shows that the incidence
of miscarriage in pregnant women with chronic HBV
infection is significantly higher than that in non-HBV
controls. The association remain unchanged after adjust-
ment for other possible maternal confounders such as
age, parity and history of abortion. This result is surpris-
ing. We for the first time report that HBV carrier status
entails a considerable increased risk of miscarriage.
The relationship between viral infections and miscar-
riage has not been well-understood. On the one hand,
several viruses such as CMV, HSV-1/2, human parvo-
virus B19 (HPV B19), adenovirus, Coxsackie B virus,
have been indicated to be causative agents of miscarriage
[20, 21]. On the other hand, the causal relationship of
other viruses with miscarriage has not been established
for some reasons. First, viral infection of the pregnant
women may not always represent fetal infection because
of the placental barrier. Second, placental viral infection
indicates risk of vertical transmission, but not always
transmission to, or disease of the fetus. Last, the intra-
uterine viral infection does not always cause morbidity
or mortality at the early stage of the fetus. For example,
the rate of miscarriage following acute varicella did not
exceed the rate of miscarriage in pregnant women
without chickenpox [22].
The question whether HBV infection in the mothers
entails an increased risk for adverse pregnancy outcomes
was raised in the 1960s [23], and has been followed by
several studies with contradictory and confusing results.
For the case–control studies [8–10], the selection bias
is a big concern. For the retrospective cohort studies
[11, 13–15], information for early pregnancy is incom-
plete. For the prospective cohort studies [7, 12], small
sample sizes (with 1576 and 1826 participants respect-
ively) are their major limitation. To the best of our know-
ledge, this is the first prospective single-center study on
HBV carriers during pregnancy to date. Our finding
implies that chronic HBV carrier status is likely to affect
placental function rather than preterm labor.
The study population had a high level of homogeneity
in that nearly all participants were ethnic Han from an
Table 4 Risk factors associated with miscarriage
Cases/Exposed Crude OR (95 % CI) Adjusted OR (95 % CI)
Age
<35 1067/19691 1 1
≥35 148/1313 2.22 (1.85–2.66) 1.17 (0.94–1.45)
Nulliparity
No 830/15897 1 1
Yes 385/5107 1.48 (1.31–1.69) 1.80 (1.54–2.11)
Education
High school/under 497/8063 1
College/above 718/12941 0.83 (0.67–1.19)
Pre-maternal BMI
<25 1049/18331 1
≥25 166/2673 1.09 (0.97–1.42)
Previous abortion
0 673/19063 1 1
1 309/1371 7.95 (6.85–9.22) 9.33 (7.97–10.92)
≥2 233/570 18.89 (15.72–22.71) 23.36 (19.10–28.57)
HBV carrier
No 1167/20491 1 1
Yes 48/513 1.71 (1.26–2.31) 1.71 (1.23–2.38)
IVF
No 1196/20853 1 1
Yes 19/151 2.37 (1.46–3.84) 1.78 (1.03–3.05)
Abbreviations: BMI body mass index, IVF in vitro fertilization
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eastern region of China and all were asymptomatic.
Although the prevalence of HBsAg (2.5 %) among preg-
nant women in this study was much lower than that
(6.1 %) in another survey conducted in a southwest
region of China in 2010 [1], its epidemiologic power is
still strong. In such a sample of more than 500 women
who were exposed to chronic HBV infection in preg-
nancy with a ratio of 1:40 to the controls and the
assumption of a baseline miscarriage risk of 5 %, the
detection of a 1.7-fold increase in the rate of miscarriage
(with 95 % CI), yielded a power of 90 %.
It should be noted that in this study asymptomatic
HBV carriers had significantly higher serum ALT levels
than non-HBV controls, suggesting that even in clinic-
ally asymptomatic infection, HBV may still produce
adverse effects on the liver. Their longer-term effects on
the liver as well as metabolic profiles await further
examinations. Asymptomatic HBV carriers can be cate-
gorized into two clinical HBV phases: immune tolerance
(IT) and inactive carrier (IC) [24]. IT patients had posi-
tive serum HBeAg and repetitive normal ALT values
(<40 IU/L) for at least 1 year. Patients with typical IT
form (very high viral load HBV-DNA ≥2 × 106 IU/mL)
have very limited liver injury, while patients with atypical
form (HBV-DNA <2 × 106 IU/mL) have a potential risk of
more severe histological lesions. IC patients had repetitive
normal ALT values (<40 IU/L) for at least 1 year, negative
HBeAg and positive HBeAb. Patients with typical IC form
have low viral load (HBV-DNA <2,000 IU/mL) and
minimal histological lesions, while patients with at-
ypical form had higher HBV-DNA (≥2,000 IU/mL)
remain problematic. Therefore, the absence of symp-
toms is not enough to accurately separate patients
with significant progressive liver injury from inactive
HBsAg carriers [25].
Our study has shown that the majority of pregnant
women maintain persistently normal levels of serum
ALT through the pregnancy. Elevation of ALT was
usually within 1–2 × ULN, and decrease to normal levels
within three months. The incidence of abnormal ALT is
0.57 % through the study. This rate seems significantly
lower than the estimated incidence rate of 3 % for
abnormal liver functions as previously reported in other
population studies [26]. A possible explanation may be
the inclusion criteria of this study, i.e. no pre-existing
chronic liver diseases, no concurrent medical diseases,
treatment-naive HBV carrier status, and normal ALT
level at study entry.
The outcome of a woman’s previous pregnancy has
profound consequences for her subsequent pregnancies.
We found that the most important predictive factor for
miscarriage is a history of spontaneous or induced
abortion, in accordance with previous studies [27, 28].
The etiology of recurrent pregnancy loss is still unclear
[29]. While induced abortion may increase the risks for
both a subsequent preterm delivery and mood disorders
substantial, the association of previous induced abortion
with subsequent miscarriage remains controversial [30].
Admittedly, our study has several limitations. First of
all, we were only able to locate very few data regarding
viral load in these HBV carriers. Thus, we were unable
to conclude any significant correlation between higher
viral loads at the time of pregnancy and adverse out-
comes. Second, some potential confounders which might
affect pregnancy outcomes have not been included. For
example, cigarette, alcohol, and caffeine consumption
may be risk factors for miscarriage. Actually, in Chinese
culture, women are discouraged from drinking alcohol
and from smoking cigarette. Most people drink tea over
coffee in China as well. Another limitation is single-
center nature of this study. Indeed, the Obstetrics &
Gynecology Hospital of Nantong University is the sole
special hospital for the treatment of women illnesses in
Nantong city, eastern China, and serves more than half
of obstetric population in this region.
Conclusion
This study reflects the clinical reality of pregnant women
and indicates that HBV carrier status confers a substantial
increased risk for miscarriage. Careful surveillance as
high-risk pregnancy is warranted. Further studies are
needed to assess the importance of factors such as disease
activity, viral characteristics, and other clinical features of
the disease.
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